Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer

Prostate

Volumn 73, Issue 12, 2013, Pages 1352-1363

  Hou, Xianzeng ^a,b   Li, Zhiguo ^a   Huang, Weize ^a   Li, Jiejie ^c   Staiger, Christopher ^c   Kuang, Shihuan ^a   Ratliff, Tim ^d   Liu, Xiaoqi ^a,d  

^a PURDUE UNIVERSITY   (United States)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c PURDUE UNIVERSITY   (United States)

^d Purdue University   (United States)

Author keywords

androgen receptor; microtubule dynamics; paclitaxel; Plk1; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CASEIN KINASE II; CYCLIN B; PACLITAXEL; POLO LIKE KINASE 1;

APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG RESPONSE; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR; MICROTUBULE DYNAMICS; PACLITAXEL; PLK1; PROSTATE CANCER;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; HUMANS; MALE; MICROTUBULES; PACLITAXEL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84881032185     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22683     Document Type: Article

References (28)

1. Schrijvers D, Van Erps P, Cortvriend J,. Castration-refractory prostate cancer: New drugs in the pipeline. Adv Ther 2010; 27 (5): 285-296.
2. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P,. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71 (18): 6019-6029.
3. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H,. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69 (21): 8386-8394.
4. Jordan MA, Wilson L,. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4 (4): 253-265.
5. Mitchison T, Kirschner M,. Dynamic instability of microtubule growth. Nature 1984; 312 (5991): 237-242.
6. Perez F, Diamantopoulos GS, Stalder R, Kreis TE,. CLIP-170 highlights growing microtubule ends in vivo. Cell 1999; 96 (4): 517-527.
7. Lansbergen G, Komarova Y, Modesti M, Wyman C, Hoogenraad CC, Goodson HV, Lemaitre RP, Drechsel DN, van Munster E, Gadella TW Jr, Grosveld F, Galjart N, Borisy GG, Akhmanova A,. Conformational changes in CLIP-170 regulate its binding to microtubules and dynactin localization. J Cell Biol 2004; 166 (7): 1003-1014.
8. Strebhardt K,. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9 (8): 643-660.
9. Eckerdt F, Yuan J, Strebhardt K,. Polo-like kinases and oncogenesis. Oncogene 2005; 24 (2): 267-276.
10. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G,. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60 (3): 240-245.
11. Reagan-Shaw S, Ahmad N,. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: Implications for the treatment of prostate cancer. FASEB J 2005; 19 (6): 611-613.
12. Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, Liu X,. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem 2011; 286 (41): 35795-35800.
13. Li H, Liu XS, Yang X, Wang Y, Wang Y, Turner JR, Liu X,. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J 2010; 29 (17): 2953-2965.
14. Li H, Liu S, Yang X, Song B, Wang Y, Liu X,. Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci USA 2010; 107 (33): 14633-14638.
15. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M,. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007; 67 (9): 955-967.
16. Staiger CJ, Sheahan MB, Khurana P, Wang X, McCurdy DW, Blanchoin L,. Actin filament dynamics are dominated by rapid growth and severing activity in the Arabidopsis cortical array. J Cell Biol 2009; 184 (2): 269-280.
17. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ,. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17 (4): 316-322.
18. Yang X, Li H, Liu XS, Deng A, Liu X,. Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. J Biol Chem 2009; 284 (42): 28775-28782.
19. Moreno-Aspitia A, Perez EA,. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009; 31 (8): 1619-1640.
20. Gottesman MM, Fojo T, Bates SE,. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2 (1): 48-58.
21. Baumert C, Hilgeroth A,. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 2009; 9 (4): 415-436.
22. Schmitt CA, Rosenthal CT, Lowe SW,. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6 (9): 1029-1035.
23. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM,. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999; 59 (7 Suppl.): 1685s-1692s.
24. Brown JM, Attardi LD,. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5 (3): 231-237.
25. Brown JM, Wilson G,. Apoptosis genes and resistance to cancer therapy: What does the experimental and clinical data tell us ? Cancer Biol Ther 2003; 2 (5): 477-490.
26. Liu XS, Song B, Liu X,. The substrates of Plk1, beyond the functions in mitosis. Protein Cell 2010; 1 (11): 999-1010.
27. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K,. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26 (39): 5793-5807.
28. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K,. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66 (11): 5836-5846.